Furthermore, the fully adjusted model, including RI, LDH, HB, albumin, serum beta 2 microglobulin, serum /urinary kappa or lambda light chains, and anti-myeloma therapy regimen, showed a significant increase in risk of adverse outcomes conferred by the serum calcium level (HR, 5.72; 95% CI, 2.09–15.63; p < 0.001; Table 5 [model 2]). The gene discussed is B2M; the disease is plasma cell myeloma.